Optomed Q3 (Review): Solid growth with a positive devices segment development - Redeye

Redeye provides an update following Optomed’s Q3 2025 report. The report was solid in our view, with a strong development in the devices segment, and the outlook remains positive. Changes have been made to our sales and OPEX forecasts in this update; however, the fair value range remains intact.

Länk till analysen i sin helhet: https://www.redeye.se/research/1136922/optomed-q3-review-solid-growth-with-a-positive-devices-segment-development?utm_source=finwire&utm_medium=RSS